TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
TG Therapeutics' stock has declined following a disappointing quarterly report, but the company remains confident in its multiple sclerosis drug. The stock's value dropped by 15%. Despite the setback, the company is reaffirming its confidence in the drug's potential.